Med. Pro Praxi 2008; 5(2): 70-73

Hormonální substituční terapie a kardiovaskulární systém

MUDr. Tomáš Fait
Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze

Názory na vztah hormonální substituční terapie a kardiovaskulárního systému se vyvíjejí. Původní představy o protektivním vlivu hormonální terapie v primární i sekundární prevenci ischemické choroby srdeční byly po zveřejnění výsledků studií HERS a WHI vystřídány obavami z vysokého rizika. Teprve recentní reanalýzy dosavadních studií přinesly racionální pohled, který dle teorie terapeutického okna potvrzuje neutrální až hraničně protektivní vliv hormonální substituce při jejím časném, indikovaném a individuálním podání. Riziko tromboembolické nemoci je obdobné jako při podávání jiných sexagenů s výhodou dlouhé anamnézy umožňující vyčlenění rizikové skupiny.

Keywords: hormonální substituční terapie, ischemická choroba srdeční, tromboembolická nemoc

Published: May 21, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fait T. Hormonální substituční terapie a kardiovaskulární systém. Med. praxi. 2008;5(2):70-73.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of HRT. Lancet 2002; 360: 942-944. Go to original source... Go to PubMed...
    2. Busch TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women. Circulation 1987; 75: 1102-1109. Go to original source... Go to PubMed...
    3. Collins P, Rosano G, Casey C et al. Management of cardiovascular risk in the peri-menopausal women: a consensus statement of European cardiologists and gynaecologists. European Heart Journal 2007; 28: 2028-2040. Go to original source... Go to PubMed...
    4. Cushman M, Legault C, Barret-Connor E et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. Circulation 1999; 100(7): 717-722. Go to original source... Go to PubMed...
    5. Daly E, Vessey MP, Hawkins MC et al. Risk of venous tromboembolism in users of HRT. Lancet 1996; 348: 977. Go to original source... Go to PubMed...
    6. Depypere HT, Tummers P, Bacquer et al. Number of women needed in a prospektive trial to prove potential benfit of hormone replacement therapy. Climacteric 1997; 10: 238-243. Go to original source... Go to PubMed...
    7. Grady D, Herrington D, Bittner V. HERS II. Cardiovascular disease outcomes during 6-8 years of hormone therapy. JAMA 2002; 288: 49-57. Go to original source... Go to PubMed...
    8. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. NEJM 1996; 335: 453-461. Go to original source... Go to PubMed...
    9. Hulley S, Grady D, Bush T et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart desease in postmenopausal women. JAMA 1998; 280: 605-613. Go to original source... Go to PubMed...
    10. Manson JE, Allison MA, Rossouw JE et al. Estrogen therapy and coronary-artery calcification. NEJM 2007; 356: 2591-2602. Go to original source... Go to PubMed...
    11. Rossouw JER, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297(13): 1465-1477. Go to original source... Go to PubMed...
    12. Salpeter SR, Walsh JME, Greyber E et al. Mortality associated with hormone replacement therapy in younger and older women. J Gen Intern Med 2004; 19: 791-804. Go to original source... Go to PubMed...
    13. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-432. Go to original source... Go to PubMed...
    14. Seed M, Knopp RH. Estrogens, lipoproteins and cardiovascular risk factors: an update following the randomized placebo-controlled trials of HRT. Curr Opinions Lipidol 2004; 13: 459-467. Go to original source... Go to PubMed...
    15. Schlipak MG, Angeja BG, Go AS et al. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 2001; 104: 2300-2304. Go to original source... Go to PubMed...
    16. Straczek C, Oger E, Yon de Jonage-Canonico MB et al. Prothrobotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112(22): 3495-3500. Go to original source... Go to PubMed...
    17. WHI Steering Commitee. Effect of CEE in postmenopausal women. JAMA 2004; 291: 1701-1712. Go to original source... Go to PubMed...
    18. Writing Group for the Women´s Health Initiative Investigators, JAMA 2002; 288: 321-333.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.